Fang J, Metter EJ, et al. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/mL.
How did the USPSTF arrive at this recommendation? US Preventative Services Task Force website. Available at:
http://www.uspreventiveservicestaskforce.org/prostatecancerscreening/prostatecancerfaq.htm. Published May 2012. Accessed September 12, 2012.
Members of the Prostate-Specific Antigen Best Practice Statement Panel (2009). Prostate-Specific Antigen Best Practice Statement: 2009 Update. Available at:
http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf. Accessed April 17, 2013.
Prostate cancer screening. EBSCO DynaMed website.
http://www.ebscohost.com/dynamed. Updated March 15, 2013. Accessed April 17, 2013.
Prostate-Specific Antigen (PSA) Test. National Cancer Institute website. Available at:
http://www.cancer.gov/cancertopics/factsheet/Detection/PSA. Updated July 24, 2012. Accessed April 17, 2013.
Screening for prostate cancer: current recommendation. US Preventative Services Task Force website. Available at:
http://www.uspreventiveservicestaskforce.org/prostatecancerscreening.htm. Published May 2012. Accessed April 17, 2013.
Stephan C, Stroebel G, et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
5/6/2009 DynaMed's Systematic Literature Surveillance
http://www.ebscohost.com/dynamed: Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study.
N Engl J Med.